{
    "clinical_study": {
        "@rank": "38359", 
        "brief_summary": {
            "textblock": "Primary Objective :\n\n      To determine whether pre-treatment levels of anti-mullerian hormone predicts ovarian\n      follicular reserve post adjuvant or neoadjuvant chemotherapy for breast cancer and\n      chemotherapy induced amenorrhea (CIA).\n\n      Secondary Objective\n\n        -  To evaluate the comparative ovarian toxicity of differing neo-adjuvant/ adjuvant\n           chemotherapy regimens.\n\n        -  To assess the correlation between CIA and depletion of ovarian follicular reserve.\n\n        -  To partly externally validate preceding studies of anti-mullerian hormone levels in\n           patients receiving neo-adjuvant/ adjuvant chemotherapy for breast cancer.\n\n        -  To determine the efficacy of GNRH agonists in preservation of ovarian follicles in\n           premenopausal women treated with adjuvant or neo-adjuvant chemotherapy for breast\n           cancer. Administration of GNRH agonists is dependent on the treating oncologist's\n           judgment of the patient's case and practices and is not to be influenced by study\n           participation."
        }, 
        "brief_title": "Anti-Mullerian Hormone Study. ICORG 10-16, V2", 
        "condition": [
            "Premenopausal Breast Cancer", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Type of Study: Translational Study\n\n      Sample Type: A 10mL blood sample will be collected in red vacutainer tubes (no\n      anticoagulant, no gel) from each patient at the designated time points +/- 7days. Blood\n      should preferably be collected in the follicular phase of the menstrual cycle.\n\n      Time of Sample procurement:\n\n        -  1st Sample: Pre-Chemotherapy (\u2264 14 days pre-treatment)\n\n        -  2nd Sample: e.g. before cycle 3, if undergoing a 4 cycle regimen or before cycle 4 in a\n           6 cycle regimen. (If the chemotherapy regimen changes following the commencement of\n           chemotherapy &/or after surgery, then blood samples will be taken at the time points\n           determined by the original plan i.e. if a patient was to have 6 cycles of chemotherapy\n           and this was then changed to 4 cycles samples will be taken before cycle 4)\n\n        -  3rd sample: 3 weeks following the last dose of chemotherapy\n\n        -  4th sample: 3 months following the last dose of chemotherapy\n\n        -  5th sample: 6 months following the last dose of chemotherapy\n\n        -  6th sample: 1 year following the last dose of chemotherapy\n\n        -  7th sample: 2 years following the last dose of chemotherapy\n\n        -  8th sample: 3 years following the last dose of chemotherapy\n\n      Patient's menstrual status including the commencement date of last menstrual period or the\n      use of Intra Uterine Devices (IUD) and FSH, LH and E2 levels will be documented on the\n      Baseline Assessment CRF.\n\n      FSH, LH and E2 levels will also be measured at each time point and documented on the\n      Follow-up Assessment CRF."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Documented histological diagnosis of invasive breast cancer\n\n          2. Patient due to be treated with chemotherapy (neoadjuvant or adjuvant)[Patients\n             treated with GNRH agonist or adjuvant Herceptin or participating in other clinical\n             trials are also eligible]\n\n          3. Female patients aged between 18 and 42 years\n\n          4. Premenopausal status as defined by a hormone profile (FSH, LH, E2 within the\n             pre-menopausal range as defined by local lab).\n\n             OR\n\n             -The last menstrual period had to be within 180 days\n\n             OR\n\n             -An IUD is used for contraception\n\n          5. Karnofsky score greater or equal to 70\n\n          6. Ability to provide written informed consent\n\n        Exclusion Criteria:\n\n          1. Patients with hypothalamic/pituitary disorder\n\n          2. History of ovarian tumour\n\n          3. Current pregnancy (pregnancy test as per hospital standard prior to treatment)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "42 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Premenopausal breast cancer patients who are to receive chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726322", 
            "org_study_id": "ICORG 10-16"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Bryan Hennessy, Dr", 
                    "phone": "01-8092010"
                }, 
                "facility": {
                    "address": {
                        "city": "Drogheda", 
                        "country": "Ireland", 
                        "state": "Louth", 
                        "zip": "Co"
                    }, 
                    "name": "Our Lady of Lourdes Hospital"
                }, 
                "investigator": {
                    "last_name": "Bryan Hennessy, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "021-4546400"
                }, 
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Cork University Hospital"
                }, 
                "investigator": {
                    "last_name": "Seamus O'Reilly, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "021-4542807"
                }, 
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Bon Secours Hospital"
                }, 
                "investigator": {
                    "last_name": "Brian Bird, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01-4103000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "St James Hospital"
                }, 
                "investigator": {
                    "last_name": "John Kennedy, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01-2214000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "St Vincent's University Hospital"
                }, 
                "investigator": {
                    "last_name": "Janice Walshe, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01- 414 2000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "The Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Janice Walshe, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01-8092373"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland", 
                        "zip": "9"
                    }, 
                    "name": "Beaumont Hospital"
                }, 
                "investigator": {
                    "last_name": "Oscar Breathnach, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "091-544805"
                }, 
                "facility": {
                    "address": {
                        "city": "Galway", 
                        "country": "Ireland"
                    }, 
                    "name": "Galway University Hospital"
                }, 
                "investigator": {
                    "last_name": "Maccon Keane, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "071- 9171111"
                }, 
                "facility": {
                    "address": {
                        "city": "Sligo", 
                        "country": "Ireland"
                    }, 
                    "name": "Sligo General Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Martin, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "051-848000"
                }, 
                "facility": {
                    "address": {
                        "city": "Waterford", 
                        "country": "Ireland"
                    }, 
                    "name": "Waterford Regional Hospital"
                }, 
                "investigator": {
                    "last_name": "Miriam O'Connor, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Study to Determine Alteration of Anti-mullerian Hormone (AMH) Concentrations in Premenopausal Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Breast Cancer", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ireland: Health Information and Quality Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of AMH levels from before starting chemotherapy to predefined intervals concluding at 3 years post completion of chemotherapy", 
            "safety_issue": "No", 
            "time_frame": "AMH levels will be taken at specified intervals until 3 years post chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726322"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Frequency of chemotherapy induced amenorrhea in patients treated with and without GNRH agonists.", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years post chemotherapy"
        }, 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}